Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037368 | 0.89 | TLR7 (0.80) | TLR7 | |
| SCHEMBL20993121 | 0.89 | TLR7 (0.80) | TLR7 | |
| SCHEMBL31410728 | 0.89 | TLR7 (0.80) | TLR7 | |
| SCHEMBL30037437 | 0.87 | TLR7 (1.00) | TLR7 | |
| SCHEMBL20212200 | 0.87 | TLR7 (1.00) | TLR7 | |
| SCHEMBL20212267 | 0.85 | TLR7 (0.77) | TLR7 | |
| SCHEMBL30036415 | 0.85 | TLR7 (0.75) | TLR7 | |
| SCHEMBL30035575 | 0.85 | TLR7 (0.77) | TLR7 | |
| SCHEMBL30036392 | 0.85 | TLR7 (0.75) | TLR7 | |
| SCHEMBL20212217 | 0.85 | TLR7 (0.75) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| CN-110177780-B | Pyrimidine compounds containing acidic groups | 阿普罗斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | Apros Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | Apros Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| EP-3548478-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2018106606-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000826-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS AS TLR7 MODULATORS | TLR7, TLR9, STING1 | TLR7 1/4885 |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | TLR7 2/4885 |
| US-20190314372-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | TLR7 2/4885 |
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | TLR7 2/4885 |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | TLR7 1/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | TLR7 1/4885 |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.